RT Journal Article
T1 Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review.
A1 Ortiz-Sanjuán, Francisco
A1 Blanco, Ricardo
A1 Riancho-Zarrabeitia, Leyre
A1 Castañeda, Santos
A1 Olivé, Alejandro
A1 Riveros, Anne
A1 Velloso-Feijoo, María L
A1 Narváez, Javier
A1 Jiménez-Moleón, Inmaculada
A1 Maiz-Alonso, Olga
A1 Ordóñez, Carmen
A1 Bernal, José A
A1 Hernández, María V
A1 Sifuentes-Giraldo, Walter A
A1 Gómez-Arango, Catalina
A1 Galíndez-Agirregoikoa, Eva
A1 Blanco-Madrigal, Juan
A1 Ortiz-Santamaria, Vera
A1 del Blanco-Barnusell, Jordi
A1 De Dios, Juan R
A1 Moreno, Mireia
A1 Fiter, Jordi
A1 de los Riscos, Marina
A1 Carreira, Patricia
A1 Rodriguez-Valls, María J
A1 González-Vela, M Carmen
A1 Calvo-Río, Vanesa
A1 Loricera, Javier
A1 Palmou-Fontana, Natalia
A1 Pina, Trinitario
A1 Llorca, Javier
A1 González-Gay, Miguel A
K1 Adulto
K1 Quimioterapia combinada
K1 Femenino
K1 Humanos
K1 Inmunosupresores
K1 Proteína antagonista del receptor de interleucina 1
K1 Masculino
K1 Mediana edad
K1 Prednisona
K1 Estudios retrospectivos
K1 Enfermedad de Still del adulto
AB Adult-onset Still's disease (AOSD) is often refractory to standard therapy. Anakinra (ANK), an interleukin-1 receptor antagonist, has demonstrated efficacy in single cases and small series of AOSD. We assessed the efficacy of ANK in a series of AOSD patients. Multicenter retrospective open-label study. ANK was used due to lack of efficacy to standard synthetic immunosuppressive drugs and in some cases also to at least 1 biologic agent. Forty-one patients (26 women/15 men) were recruited. They had a mean age of 34.4 ± 14 years and a median [interquartile range (IQR)] AOSD duration of 3.5 [2-6] years before ANK onset. At that time the most common clinical features were joint manifestations 87.8%, fever 78%, and cutaneous rash 58.5%. ANK yielded rapid and maintained clinical and laboratory improvement. After 1 year of therapy, the frequency of joint and cutaneous manifestations had decreased to 41.5% and to 7.3% respectively, fever from 78% to 14.6%, anemia from 56.1% to 9.8%, and lymphadenopathy from 26.8% to 4.9%. A dramatic improvement of laboratory parameters was also achieved. The median [IQR] prednisone dose was also reduced from 20 [11.3-47.5] mg/day at ANK onset to 5 [0-10] at 12 months. After a median [IQR] follow-up of 16 [5-50] months, the most important side effects were cutaneous manifestations (n = 8), mild leukopenia (n = 3), myopathy (n = 1), and infections (n = 5). ANK is associated with rapid and maintained clinical and laboratory improvement, even in nonresponders to other biologic agents. However, joint manifestations are more refractory than the systemic manifestations.
PB Lippincott, Williams & Wilkins
SN 0025-7974
YR 2015
FD 2015-09
LK http://hdl.handle.net/10668/2626
UL http://hdl.handle.net/10668/2626
LA en
NO Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, Castañeda S, Olivé A, Riveros A, et al. Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review. Medicine (Baltimore). 2015                         ; 94(39):e1554
NO This work was  partially supported by RETICS Programs, RD08/0075m (RIER), and RD12/0009/0013 from ‘‘Instituto de Salud Carlos III’’ (ISCIII) (Spain)
DS RISalud
RD Apr 8, 2025